For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Sage Therapeutics Inc (NASDAQ: SAGE) closed the day trading at $12.89 down -3.30% from the previous closing price of $13.33. In other words, the price has decreased by $-3.30 from its previous closing price. On the day, 0.8 million shares were traded. SAGE stock price reached its highest trading level at $13.46 during the session, while it also had its lowest trading level at $12.89.
Ratios:
For a better understanding of SAGE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.49 and its Current Ratio is at 10.51. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on April 17, 2024, Downgraded its rating to Underperform and sets its target price to $14 from $24 previously.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 09 ’23 when Barrett Elizabeth bought 2,000 shares for $18.64 per share. The transaction valued at 37,279 led to the insider holds 3,000 shares of the business.
Barrett Elizabeth bought 1,000 shares of SAGE for $50,500 on May 09 ’23. The Director now owns 1,000 shares after completing the transaction at $50.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SAGE now has a Market Capitalization of 774775360 and an Enterprise Value of 53203136. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.96 while its Price-to-Book (P/B) ratio in mrq is 0.97. Its current Enterprise Value per Revenue stands at 0.615 whereas that against EBITDA is -0.098.
Stock Price History:
The Beta on a monthly basis for SAGE is 0.93, which has changed by -0.7176446 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, SAGE has reached a high of $59.99, while it has fallen to a 52-week low of $10.92. The 50-Day Moving Average of the stock is -34.73%, while the 200-Day Moving Average is calculated to be -44.16%.
Shares Statistics:
Over the past 3-months, SAGE traded about 993.79K shares per day on average, while over the past 10 days, SAGE traded about 1426670 shares per day. A total of 60.04M shares are outstanding, with a floating share count of 49.05M. Insiders hold about 18.39% of the company’s shares, while institutions hold 94.71% stake in the company. Shares short for SAGE as of 1711584000 were 8602649 with a Short Ratio of 8.66, compared to 1709164800 on 7907106. Therefore, it implies a Short% of Shares Outstanding of 8602649 and a Short% of Float of 21.59.
Earnings Estimates
The market rating for Sage Therapeutics Inc (SAGE) is a result of the insights provided by Spirit Airlines, Inc. analysts actively involved in the assessment.The consensus estimate for the next quarter is $12.89, with high estimates of $1.39 and low estimates of $19.14.
